TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CardieX ( (AU:CDX) ) has shared an announcement.
Cardiex Limited announced the successful results of its fully underwritten, non-renounceable pro-rata entitlement offer, raising approximately $4.1 million. Together with a prior institutional placement, the company has secured a total of $6.5 million in funds. The entitlement offer, which was well-supported by shareholders, saw a take-up of approximately 50.3%, with the remaining shares allocated to underwriters. The funds will support Cardiex’s operations and potentially strengthen its position in the medical technology industry.
More about CardieX
Cardiex is a company focused on advancing medical technology in vascular health, offering products such as medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Their products are based on their market-leading SphygmoCor® vascular biomarker technology, and the company is listed on the Australian Stock Exchange (ASX:CDX).
Average Trading Volume: 297,697
Technical Sentiment Signal: Sell
Current Market Cap: A$22M
For an in-depth examination of CDX stock, go to TipRanks’ Overview page.